Naltrexone: Alcohol and Opioid Treatment, Side Effects and Safety

Naltrexone blocks opioid receptors. It is used in treatment of alcohol dependence and to block the effects of externally taken opioids as part of an addiction-management plan. Oral tablets and extended-release injections are different formulations with different instructions and availability. Vivitrol is an example of an injectable brand; local product information determines what is licensed and supplied where you receive care. [1] [2]

Ask which condition the proposed prescription addresses and what improvement would look like. Reduced alcohol consumption, maintaining abstinence and preventing return to opioid use are related but distinct goals. A medication name does not establish that the same approach suits every person. The plan should be explained in terms you can recognize in daily life rather than as a promise that a tablet or injection removes addiction.

By occupying opioid receptors without activating them in the same way as an opioid agonist, naltrexone blocks opioid effects and can reduce alcohol-related craving or reinforcement. It does not supply an opioid effect and is not considered addictive. This differs from both methadone and buprenorphine, which have different mechanisms and important evidence-based roles in opioid treatment. [2]

Different mechanisms do not create a hierarchy of moral worth between treatments. Ask which option best fits your clinical circumstances, preferences and ability to begin and continue treatment. Do not select an antagonist simply because it sounds more medication-free than an agonist treatment. The relevant questions are safety, effectiveness and a sustainable care plan, not whether one medicine carries less stigma in a social conversation.

Naltrexone can support alcohol-use-disorder treatment, but it does not treat the dangerous physical complications of alcohol withdrawal. A person with withdrawal risk needs a separate medical assessment before reducing or stopping alcohol. Withdrawal management and ongoing addiction treatment should be connected; completing a short detox episode does not address every factor that contributes to returning to drinking. [2] [4]

Discuss the pattern of drinking, previous withdrawal episodes, seizures and other medicines. Ask the clinician to identify what needs attention first and where that care can safely take place. This guide does not set a number of drinks at which home withdrawal becomes safe or provide a starting schedule. Confusion, a seizure, severe agitation or serious illness during withdrawal warrants urgent medical care rather than waiting for a routine medication appointment.

Naltrexone can precipitate opioid withdrawal when opioids are still affecting the body in a person who is physically dependent. It is contraindicated during acute opioid withdrawal, current opioid dependence and treatment with opioid analgesics under the cited tablet labeling. Methadone and buprenorphine are also relevant opioid exposures. A clinician must determine readiness; simply counting days yourself is not a reliable substitute for assessment. [1]

Tell the team about prescribed pain medicines, cough preparations containing opioids, nonprescribed substances and recent treatment elsewhere. Be honest about uncertain products or timing. This information is needed to protect you, not to judge you. Do not stop established methadone or buprenorphine treatment independently in order to start naltrexone. Any proposed transition needs a specialist plan that considers the difficulty of the transition and the risk of being left without effective treatment.

Trying to overcome opioid blockade by taking more opioids can cause a fatal overdose. After a period without opioids, tolerance may be lower; returning to a previously used amount can therefore be dangerous, including after naltrexone is stopped or an injection’s effect wears off. Naltrexone is not a guarantee against overdose and is not a replacement for access to emergency naloxone. [2] [3]

Ask for an overdose-prevention plan before treatment begins. Discuss rescue medication, how someone close to you can recognize an emergency and whom to contact if treatment is interrupted. If a person is unresponsive or breathing abnormally, call local emergency services and use available naloxone according to its instructions. Do not wait to see whether naltrexone will protect them. Emergency assessment remains necessary even when someone initially improves.

A daily tablet and a long-acting injection create different practical tasks. Tablets require a reliable routine; injections require an appropriate clinical service and return appointments. Neither formulation should be changed or substituted independently. Ask about the exact product, how appointments or supplies will be arranged and what happens if a dose or visit is missed. The choice should take account of access and your preferences, not just a general claim that one form is easier. [2]

Before leaving the first appointment, write down who will respond to questions and how follow-up is organized. Mention upcoming travel or an expected change of residence. A workable treatment plan anticipates these details instead of waiting for medication to run out. Do not double tablets after a missed dose or attempt to administer an injectable preparation without the qualified service responsible for it.

Nausea, headache, dizziness, tiredness, sleep changes and other unwanted effects can occur. Injectable treatment can also cause local reactions. Report persistent effects rather than assuming they must be endured to demonstrate commitment to recovery. Describe when they began, whether they follow treatment and how they affect eating, work or sleep. Avoid driving when impaired. [2] [3]

Keep the description separate from your conclusion about the cause. Feeling unwell may relate to medication, withdrawal, another illness or a combination. A brief timeline is useful, but it should not delay care for severe symptoms. Ask what can be reviewed routinely and what should prompt same-day or emergency assessment. The answer should fit the actual formulation and your health history.

Signs of liver injury, such as yellowing skin or eyes, dark urine or persistent significant abdominal pain, need prompt medical assessment. Severe allergy or breathing difficulty is an emergency. With injections, intense or worsening pain, substantial swelling, an open wound or other concerning injection-site changes should be assessed rather than dismissed as an ordinary sore muscle. [2] [3]

Tell the prescriber about liver disease, recent illness, pregnancy or breastfeeding and all other medicines. Ask what examination or blood testing is appropriate and who will review the results. An old normal test does not establish that new symptoms are harmless. This overview cannot determine whether a symptom is caused by naltrexone or decide whether your next dose is appropriate during suspected serious illness.

Naltrexone’s established addiction-treatment role should not be confused with being a routine antidepressant, antipsychotic or mood stabilizer. Depression, anxiety, trauma symptoms and suicidal thoughts require their own assessment, even when alcohol or opioid treatment is improving. Report worsening mood or suicidal thoughts promptly; use emergency services if you cannot stay safe. [3]

Ask whether one clinician coordinates the medication and mental health plans. Describe how substance use, mood and sleep have changed over time without assuming one explains all the others. The co-occurring-needs overview addresses that broader assessment. It does not establish that naltrexone is appropriate for you, nor that a residential setting can meet every withdrawal or psychiatric need.

Because naltrexone blocks opioid effects, pain management can require special planning. Tell dentists, surgeons and emergency clinicians that you take it, including the date of a recent injection. Carry treatment information so it is available if you cannot explain it. Do not try to solve inadequate pain relief by increasing an opioid dose yourself. The clinical team must consider an appropriate alternative or supervised approach. [1] [3]

Before an elective procedure, ask the treating teams to communicate. A plan should cover pain treatment, any medication interruption and when addiction care will resume. Do not independently skip naltrexone to prepare for a procedure. The risks of relapse, reduced tolerance and untreated pain need to be considered together, not handed to you as separate conflicting instructions.

Naltrexone itself does not usually require a dependence-withdrawal taper, but stopping still deserves a clinical plan. The protection it provides against return to opioid or alcohol use may no longer be present, and overdose risk after opioid abstinence is important. Treatment duration should be reviewed individually rather than dictated by an arbitrary detox deadline. [2]

Before stopping, agree what follow-up will continue and how to seek help if cravings or substance use returns. Review social support, mental health treatment and emergency planning. A return to use is a reason to reassess care, not evidence that asking for help has failed. Medication and ongoing support can remain useful for different lengths of time in different people.

Is naltrexone the same as naloxone?

No. They have different treatment roles. Naloxone is used for emergency opioid-overdose reversal; naltrexone is used in ongoing addiction care. Check the name carefully and ask a pharmacist when uncertain. [3]

Does naltrexone make drinking or opioid use safe?

No. It is not protection against every harm, and attempting to overcome opioid blockade is dangerous. A treatment plan should address safety independently of whether you feel a substance’s usual effect.

What should I bring to a review?

Bring the exact medicine, recent substance-use history, injection dates if relevant, other prescriptions and your main questions. The medication-review checklist helps organize that information.

1. DailyMed: Naltrexone hydrochloride tablet labeling.
2. SAMHSA: Naltrexone treatment information.
3. MedlinePlus: Naltrexone.
4. ASAM: Alcohol withdrawal management guideline.
5. CDC: Evidence-based treatment of opioid use disorder.

Educational information only. Local product labeling and an individual clinical assessment determine treatment. Inclusion is not a statement that COGNIFUL prescribes or supplies this medicine. Return to the medication library.